NCT02464059View on ClinicalTrials.gov

Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

April 15, 2020

Study Completion Date

April 15, 2020

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Vitamin D3

Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.

Trial Locations (2)

21224

Johns Hopkins Clinical Research Unit, Baltimore

27517

Meadowmont Pulmonary Research Clinic, Chapel Hill

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT02464059 - Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD | Biotech Hunter | Biotech Hunter